X4 Pharmaceuticals, Inc (XFOR) Profit Margins
Over the twelve months to 2026-06-30, X4 Pharmaceuticals, Inc (XFOR) had gross margin 81.5%, operating margin -554.7%, net margin -568.8%, free cash flow margin -528.4%, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
XFORX4 Pharmaceuticals, IncFollow XFOR — free
—
Price chart with a free account
- Market cap
- 321.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 3 Nov, in 10 days
| Line | FY2020 Dec 20 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|
| Gross margin | — | 68.8% | 83.6% | 81.5% | |
| Operating margin | -1995.8% | -1423.6% | -247.4% | -554.7% | |
| Net margin | -2071.0% | -1464.6% | -225.6% | -568.8% | |
| FCF margin | -2006.0% | -5132.1% | -243.8% | -528.4% |
USD millions · SEC XBRL
X4 Pharmaceuticals, Inc — questions
- What is X4 Pharmaceuticals, Inc's gross margin?
- 81.5% over the twelve months to 2026-06-30.
- What is X4 Pharmaceuticals, Inc's operating margin?
- -554.7% over the twelve months to 2026-06-30.
- What is X4 Pharmaceuticals, Inc's net profit margin?
- -568.8% over the twelve months to 2026-06-30.
Every figure on this page comes from X4 Pharmaceuticals, Inc's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.